Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 16, 2024 10:58am
RE:RE:RE:RE:RE:Over 100 posts by our resident bashing team in the last week
Heineman stated in the Q3 2024 Conference Call: " Our main priorities are to advance our planned registrational studies in breast and pancreatic cancer." ...." our next planned
...more
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 15, 2024 8:41pm
RE:RE:RE:RE:RE:Over 100 posts by our resident bashing team in the last week
Thomas Heineman continued -- "I would now like to move to the Goblet study and our opportunity in gastrointestinal cancers. So far, we have evaluated Pela based therapies in first line metastatic
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 23, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 15, 2024 8:25pm
RE:RE:RE:RE:Over 100 posts by our resident bashing team in the last week
inthno - you need to listen to the Q3 CC more carefully, since below is what Thomas Heineman exactly stated - confirming that mBC will seek Accelerated Approval. " After discussions with
...more
(217)
•••
inthno
X
View Profile
View Bullboard History
Comment by
inthno
on Nov 15, 2024 8:01pm
RE:RE:RE:Over 100 posts by our resident bashing team in the last week
Just for clarification, ONC is NOT running a registration study as some suggest for the next mbc trial.... It is being set up differently but they clearly state that it is a registration enabling
...more
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 15, 2024 7:37pm
RE:Oncolytics Biotech Announces Key Progress & Upcoming Studies
BRACELET-1 efficacy data in HR+/HER2- metastatic breast cancer The recently reported final BRACELET-1 study results provide clear evidence of pelareorep's ability to improve outcomes in patients
...more
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 15, 2024 7:36pm
Oncolytics Biotech Announces Key Progress & Upcoming Studies
October 04, 2024 - Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path "We're
...more
(5341)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 15, 2024 7:28pm
RE:RE:Over 100 posts by our resident bashing team in the last week
Bracelet-1 successfully repeated and validated the results of IND-213 Phase 2 clinical study. Now ONCY is preparing to run a registration study that will seek an Accelerated Approval for pelareorep
...more
(95)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Nov 15, 2024 7:04pm
RE:Over 100 posts by our resident bashing team in the last week
utter BS Peladan... ONCY could have run a Phase III 7 years ago... and if they'd repeated the results from IND-213, they'd already be treating patients... Point the finger at the stellar ONC
...more
(207)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 15, 2024 4:35pm
RE:Over 100 posts by our resident bashing team in the last week
Investing should not be emotional... you stupid clucks sure like to twist and spin things... just like a bleeding heart liberal.
(480)
•••
Peladawn
X
View Profile
View Bullboard History
Post by
Peladawn
on Nov 15, 2024 2:20pm
Over 100 posts by our resident bashing team in the last week
All posting to try to destroy oncy to show their heartwarming compassion for cancer sufferers and their families. The garbage of humanity.....you must be so proud!
(95)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Nov 15, 2024 2:05pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
I thought these were renamed from Phase III, to "registration enabling" trials, which is just word salad. Means nothing... almost like the company's valuation.
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Nov 15, 2024 12:10pm
RE:RE:RE:Posted on Linken
Matters less and less everyday. Can't wait for Notable to come up with info totally unrelated to ONC.
(207)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 15, 2024 11:54am
RE:RE:Posted on Linken
I'm sure glad stock price does not matter... be patient... I'm am told from a "relaible" source on here that negotiations are taking place...
(137)
•••
fasttrack5
X
View Profile
View Bullboard History
Comment by
fasttrack5
on Nov 15, 2024 12:23am
RE:Posted on Linken
Just providing a post from today on Linken. a refresher then :) RJ
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >